Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGESTA: FMT for Severe Complicated CDI
NCT02968511Withdrawn
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2016
- Primary completion
- Nov 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label, single-arm trial of fecal microbiome transplant in Clostridioides difficile infection (CDI), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Safety - adverse events at 30 days. Planned start Sep 2016; status: withdrawn.
02
Drugs
fecal microbiome transplant
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02968511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968511.